# Immunovant, Inc.: insider transactions

IMVT · Nasdaq · CIK 1764013 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/imvt.md) · [Financials](/companies/imvt/financials.md) · [Filings](/companies/imvt/filings.md) · [Insiders](/companies/imvt/insiders.md)

## All transactions: 12

Non-derivative transactions reported on Forms 4, newest first. Codes P (purchase) and S (sale) are open-market trades. Reported price is as stated on the form, not a market price. Filter with ?type= `open-market`, `purchase`, `sale`.

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-21 | [Stout Jay S](/insiders/1702969.md) | Chief Technology Officer, Officer | Sale (S) | 2,595 | $28.94 | $75.1k | [Form 4](/filings/0001764013-26-000114.md) |
| 2025-12-12 | [Roivant Sciences Ltd.](/insiders/1635088.md) | Director, 10% owner | Purchase (P) | 16,666,666 | $21.00 | $350.0m | [Form 4](/filings/0001140361-25-045409.md) |
| 2025-01-13 | [Roivant Sciences Ltd.](/insiders/1635088.md) | Director, 10% owner | Purchase (P) | 16,845,010 | $20.00 | $336.9m | [Form 4](/filings/0001140361-25-001188.md) |
| 2023-10-02 | [Roivant Sciences Ltd.](/insiders/1635088.md) | Director, 10% owner | Purchase (P) | 1,526,316 | $38.00 | $58.0m | [Form 4](/filings/0001140361-23-046976.md) |
| 2023-10-02 | [Roivant Sciences Ltd.](/insiders/1635088.md) | Director, 10% owner | Grant or award (A) | 4,473,684 | $38.00 | $170.0m | [Form 4](/filings/0001140361-23-046976.md) |
| 2022-10-06 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Purchase (P) | 416,667 | $6.00 | $2.5m | [Form 4](/filings/0001140361-22-036652.md) |
| 2021-08-02 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Other (J) | 17,021,276 | not reported | not reported | [Form 4](/filings/0001104659-21-099083.md) |
| 2020-09-17 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Other (J) | 8,773,969 | not reported | not reported | [Form 4](/filings/0001104659-20-106546.md) |
| 2020-09-04 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Purchase (P) | 380,000 | $33.00 | $12.5m | [Form 4](/filings/0001104659-20-102701.md) |
| 2020-05-12 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Other (J) | 8,773,969 | not reported | not reported | [Form 4](/filings/0001104659-20-061795.md) |
| 2020-04-16 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Purchase (P) | 1,034,483 | $14.50 | $15.0m | [Form 4](/filings/0001104659-20-048301.md) |
| 2019-12-18 | [Roivant Sciences Ltd.](/insiders/1635088.md) | 10% owner | Other (J) | 36,919,967 | $10.00 | $369.2m | [Form 4](/filings/0001104659-19-075134.md) |

Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 30, 2026, 16:48 ET. No prices; not investment advice.